Compare Novartis AG (NVS) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SMX Security Matters plc — how do they compare? Novartis AG trades at $139.66 (market cap $262.64B), while SMX Security Matters plc trades at $17.92 (market cap $19.09M). The key difference: Novartis AG is far larger — about 13758× SMX Security Matters plc's market cap, and Novartis AG pays a 3.44% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals.
| NVS | SMX | |
|---|---|---|
Market Cap | $262.64B | $19.09M |
Sector | Health | Technology |
52-Week High | $168.62 | $74.08K |
52-Week Low | $121.80 | $12.87 |
Enterprise Value | $303.97B | -$12.23M |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
SMX trades at $17.88, down 8.21% on the day, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $169.18 million for 2025, with negative cash flow from operations but positive net cash flow due to financing. Recent news highlights expansion of its digital material passport platform for plastics and precious metals, targeting sustainability and supply chain verification markets.
The outlook hinges on commercialization success amid steep losses. Opportunities exist in regulatory tailwinds for recycled materials, but high cash burn and negative ROE pose significant risks. Investor sentiment is cautiously optimistic due to technology potential, yet profitability remains a distant milestone.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
